Thar reinvents known, safe on-the-market drugs by improving their clinical performance and economic benefits. We transform intravenous drugs into oral drugs, thus eliminating the cost of IV drug administration, a $34 billion annual cost paid by health systems, patients and insurers. Our lead product is an oral form of an existing $2.1 billion IV-only bone metastasis drug that can save up to $3,900 per patient per year in IV administration costs.